Skip to main content
Full access
Letter to the Editor
Published Online: 1 September 2004

ECT in Delusional Depression With Multiple Sclerosis

Publication: American Journal of Psychiatry
To the Editor: ECT has been used effectively to treat major depression associated with multiple sclerosis (1, 2). However, concerns remain that ECT might exacerbate multiple sclerosis by increasing the size and number of plaques and/or periplaque edema (1, 2).
Ms. A, a 51-year-old woman, had her first multiple sclerosis symptoms 7 years ago. A magnetic resonance imaging (MRI) proton-density-weighted axial brain scan performed 1 year later at a specialized center for multiple sclerosis showed ventricular enlargement and several multiple white matter lesions in the right part of the brainstem and bilaterally in the periventricular and subcortical areas.
Five years after the onset of multiple sclerosis, Ms. A was first hospitalized in the psychiatric ward for major depression and responded well to sertraline, 100 mg/day. One year later, a significant deterioration required hospitalization in the neurology ward followed by hospitalization in the psychiatric ward for severe catatonic delusional major depression (DSM-IV-TR) necessitating tube feeding.
ECT was required to obtain rapid improvement in this life-threatening situation. A pre-ECT brain computerized tomography scan showed moderate cortical and subcortical atrophy. ECT stimuli were delivered bilaterally by a Thymatron Tm, DG-100%=504 microcoulomb (brief-pulse) device. Anesthesia was induced with intravenous methohexital (1 mg/kg) followed by intravenous succinylcholine (1 mg/kg) and oxygenation with 100% oxygen. Improvement was seen after the third session and persisted during the subsequent 11 consolidation ECT pulse sessions. Ms. A’s total score on the 17-Item Hamilton Depression Rating Scale was 26 before ECT and 10 after ECT. Haloperidol (15 mg/day) was also prescribed.
Neither significant confusion nor memory impairment suggesting the encephalopathic effect of ECT was observed, and there was neither clinical evidence of exacerbation nor remission of neurological multiple sclerosis symptoms. Brain MRI after ECT showed no change compared to the first MRI performed before ECT. Three months later, Ms. A was still in remission while being treated with venlafaxine, 100 mg/day, and haloperidol, 5 mg/day.
This case report shows rapid significant improvement after ECT for severe life-threatening catatonic delusional major depression in a patient with multiple sclerosis. No neurological deterioration was shown after ECT.
To our knowledge, only four case reports have been published regarding patients with multiple sclerosis treated with ECT for depression and with MRIs before and after ECT. Three reports, one with six right unilateral pulse (1), a second with nine right unilateral pulse, and a third with 10 bilateral pulse (2), reported efficacy without any neurological adverse effects, while one (six with a right unilateral pulse) (2) reported significant neurological deterioration.
In conclusion, a high bilateral ECT pulse rate was not found to be associated with a greater risk of neurological deterioration in the treatment of major depression with multiple sclerosis when it is well tolerated by the patient.

References

1.
Coffey CE, Weiner D, McCall WV, Heinz ER: Electroconvulsive therapy in multiple sclerosis: a magnetic resonance imaging study of the brain. Convuls Ther 1987; 3:137–144
2.
Mattingly G, Baker K, Zorumski CF, Figiel GS: Multiple sclerosis and ECT: possible value of gadolinium-enhanced magnetic resonance scans for identifying high-risk patients. J Neuropsychiatry Clin Neurosci 1992; 4:145–151

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 1715
PubMed: 15337668

History

Published online: 1 September 2004
Published in print: September 2004

Authors

Affiliations

EMMANUELLE CORRUBLE, M.D., Ph.D.
GUY CHOUINARD, M.D., M.Sc., F.R.C.P.(C.)
PATRICK HARDY, M.D., Ph.D.
Paris, France

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share